Professor of Neurology, Johns Hopkins University School of Medicine; Neuroscience/ WW Smith Charitable Trust Professor of Neuroimmunology
Neurology
Dr. Daniel B. Drachman, MD
|
|
Give Review
Daniel Drachman works in the field of Neurology. He went to NYU School of Medicine. He has 3 awards "CMS Meaningful Use Stage 1 Certification", "Super Doctor" and "Whos Who in Medicine and Healthcare". Doctor Daniel B. Drachman, MD is a published doctor. He has 100 papers published. The most current publication "Are muscle fibers denervated in myotonic dystrophy?" Daniel Drachman accepts Medicare payments and is registered with Medicare.gov.
Publications
- A Genome-wide Association Study of Myasthenia Gravis.
- Repeated treatment with high dose cyclophosphamide for severe autoimmune Diseases.
- Specific immunotherapy of experimental Myasthenia gravis in vitro and in vivo: The Guided Missile strategy.
- High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune Diseases.
- Reduction of Disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.
- Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory Myasthenia gravis.
- Trial of celecoxib in amyotrophic lateral sclerosis.
- Pulmonary predictors of survival in amyotrophic lateral sclerosis: use in clinical trial design.
- High-dose therapy for autoimmune neurologic Diseases.
- Gene transfer of baculoviral p35 by adenoviral vector protects human Cerebral neurons from apoptosis.
- Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients.
- Adventures in clinical and basic science.
- Production and characterization of a T cell receptor transgenic mouse recognizing the immunodominant epitope of the Torpedo californica acetylcholine receptor.
- Autonomic "Myasthenia": the case for an autoimmune pathogenesis.
- Treatment of refractory Myasthenia: "rebooting" with high-dose cyclophosphamide.
- Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS.
- Motor Nerve terminal outgrowth and acetylcholine receptors: inhibition of terminal outgrowth by alpha-bungarotoxin and anti-acetylcholine receptor antibody.
- A method for the determination of drug effectiveness in onychomycosis. Trials with ketoconazole and griseofulvin ultramicrosize.
- Botulinum toxin: mechanism of presynaptic blockade.
- Effect of botulinum toxin on trophic regulation of acetylcholine receptors.
- Effect of botulinum toxin on speed of skeletal muscle contraction.
- Botulinum toxin blocks quantal but not non-quantal release of ACh at the neuroMuscular junction.
- The effect of botulinum toxin on uptake of calcium by synaptosomes.
- Targeting antigen-specific T cells by genetically engineered antigen presenting cells. A strategy for specific immunotherapy of autoimmune Disease.
- Search for the familial Alzheimer''s Disease gene.
- Absence of duplication of chromosome 21 genes in familial and sporadic Alzheimer's Disease.
- Neurotrophic regulation of dynamic properties of skeletal muscle: effects of botulinum toxin and denervation.
- Reduced acetylcholine receptors in Myasthenia gravis.
- Neurotrophic regulation of muscle cholinesterase: effects of botulinum toxin and denervation.
- Atrophy OF SKELETAL MUSCLE IN CHICK EMBRYOS TREATED WITH BOTULINUM TOXIN.
- Pharmacological denervation of skeletal muscle in chick embryos treated with botulinum toxin.
- Susceptibility of skeletal muscle to Coxsackie A2 virus infection: effects of botulinum toxin and denervation.
- The role of movement in the development of joints and related structures: the head and neck in the chick embryo.
- Ocular pseudoMyasthenia or ocular Myasthenia 'plus': a warning to clinicians.
- Myasthenic immunoglobulin accelerates acetylcholine receptor degradation.
- Internalization of IgG in motoneurons of patients with ALS: selective or nonselective?
- Are the associations between Alzheimer's Disease and polymorphisms in the apolipoprotein E and the apolipoprotein CII genes due to linkage disequilibrium?
- Present and future treatment of Myasthenia gravis.
- NeuroMuscular transmission of trophic effects.
- Trophic functions of the neuron. 3. Mechanisms of neurotrophic interactions. The role of acetylcholine as a neurotropic transmitter.
- Experimental acetylcholine blockade of the neuroMuscular junction. Effects on end plate and muscle fiber ultrastructure.
- Axonal transport to and from the motor Nerve ending.
- Potassium channel blockers potentiate impulse inhibition by local anesthetics.
- The Syndrome of arthrogryposis multiplex congenita.
- Failure of isoprinosine in amyotropic lateral sclerosis.
- Membrane myopathy: morphological similarities to Duchenne Muscular dystrophy.
- Branched-chain ketoacids reduce muscle protein degradation in Duchenne Muscular dystrophy.
- Is acetylcholine the trophic neuroMuscular transmitter?
- Periodic alteration of consciousness in the "pickwickian" Syndrome.
- Arthrogryposis multiplex congenita. Case due to disease of the Anterior horn cells.
- A new stain for quantitative measurement of sprouting at neuroMuscular junctions.
- Myeloma Neuropathy. Successful treatment of two patients and review of cases.
- Effect of neuroMuscular blockade on enzymatic activities of muscles.
- Effects of dimethyl sulfoxide on humoral immune responses to acetylcholine receptors in the rat.
- Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuroMuscular junctions.
- Corneal decompensation in mitochondrial ophthalmoplegia plus (Kearns-Sayre) Syndrome. A clinicopathologic case report.
- Neurotransmission regulates stability of acetylcholine receptors at the neuroMuscular junction.
- Low-dose-rate total lymphoid irradiation: a new method of rapid immunosuppression.
- Tolerance to acetylcholine receptor induced by AChR-coupled syngeneic cells.
- Motor Nerve outgrowth: reduced capacity for sprouting in the terminals of longer axons.
- Rapid synthesis of acetylcholine receptors at neuroMuscular junctions.
- Head drop and camptocormia.
- Effect of ketoleucine treatment on Atrophy of skeletal muscle.
- Heteroplasmy in Chronic external ophthalmoplegia: clinical and molecular observations.
- Neural regulation of mRNA for the alpha-subunit of acetylcholine receptors: role of neuroMuscular transmission.
- Nerve stimulation and denervation induce differential patterns of immediate early gene mRNA expression in skeletal muscle.
- Gangliosides elicit a T-cell independent antibody response.
- Cholinergic stimulation of skeletal muscle cells induces rapid immediate early gene expression: role of intracellular calcium.
- Myasthenic patients' IgG causes redistribution of acetylcholine receptors: freeze-fracture studies.
- Effect of myasthenic immunoglobulin on ACh receptors of cultured muscle.
- Pathogenesis of Myasthenia gravis as a disorder of acetylcholine receptors.
- Thymic muscle cells bear acetylcholine receptors: possible relation to Myasthenia gravis.
- Myasthenia gravis as a receptor disorder.
- Are muscle fibers denervated in myotonic Dystrophy?
- Blockade of acetylcholine receptors: a model of Myasthenia gravis.
- Attempts to implicate viruses in Myasthenia gravis.
- Targeting T cells in Myasthenia gravis.
- "Myopathic" changes in Chronically denervated muscle.
- Critical reexamination of the thymus immunization model of Myasthenia gravis.
- Antigen-specific suppressor macrophages induced by culture with cyclosporine A plus acetylcholine receptor.
- Prednisone treatment in Duchenne Muscular dystrophy. Long-term benefit.
- Acetylcholine receptors and Myasthenia gravis.
- Immunopathology of Myasthenia gravis.
- Dimethyl sulphoxide reduces anti-receptor antibody titres in experimental Myasthenia gravis.
- Binding affinities of anti-acetylcholine receptor autoantibodies in Myasthenia gravis.
- The biology of Myasthenia gravis.
- [A transferable "myasthenogenic" factor in the serum of patients with Myasthenia gravis (author''s transl)].
- NeuroMuscular junction in myasthenia gravis: decreased acetylcholine receptors.
- Myasthenia gravis (first of two parts).
- Induction of suppressor cells specific for AChR in experimental autoimmune Myasthenia gravis.
- A sensitive rosetting assay for detection of acetylcholine receptor antibodies using BC3H-1 cells: positive results in ''antibody-negative'' Myasthenia gravis.
- Experimental arthrogryposis caused by viral myopathy.
- Induction of apoptosis in activated T cell blasts by suppressive macrophages: a possible immunotherapeutic approach for treatment of autoimmune Disease.
- Partial T-cell receptor gene rearrangement. A source of pseudo-clonal populations in thymomas and other thymic tissues.
- Stabilization of acetylcholine receptors at neuroMuscular junctions: analysis by specific antibodies.
- Gradually increasing doses of prednisone in Myasthenia gravis. Reducing the hazards of treatment.
- Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice.
- [A transferable "Myasthenogenic" factor in the serum of patients with Myasthenia gravis.].
- Tolerance to AChR induced by AChR-coupled syngeneic cells: clonal anergy?
Schools
New York University
Beth Israel Hospital
Boston City Hospital
Mallory Institute PathBoston City Hospital
Harvard Med School
Procedures Preformed
- EMG (Electromyography)
Conditions Treated
- Anterior Horn Disease
- Ataxia
- Carpal Tunnel Syndrome
- Cerebral Artery Thrombosis
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
- Whos Who in Medicine and Healthcare
Education
-
National Institutes of Health Clinical Center -
Boston University Medical Center -
Beth Israel Deaconess Medical Center -
NYU School of Medicine
Hospital
-
Johns Hopkins Hospital
Drug Facts
| NPI NUMBER | 1720028814 | |
| NPPES Provider LastName | DRACHMAN | |
| NPPES Provider FirstName | DANIEL | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Neurology | |
| Total Claim Count | 213.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1720028814 |
| Last Name Of The Provider | DRACHMAN |
| First Name Of The Provider | DANIEL |
| View All |
Similar Doctors
|
|
Dr. Walter Royal III, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael S. Sellman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul A. Nyquist, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard Mayer, MD |
|
|
Dr. William B. Bossert, MD |
|
|
Dr. Haopeng Zheng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Glenn L. Konsky, DO |
|
|
Dr. Ilo Soovere, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Seyed Kheradmand, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Abhay R. Moghekar, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Sanjay C. Keswani, MB
This Doctor is OpenDoctor Recommended.
|